{
    "clinical_study": {
        "@rank": "18257", 
        "arm_group": {
            "arm_group_label": "KRP203", 
            "arm_group_type": "Experimental", 
            "description": "All patients to receive 3mg of KRP203 for 111days"
        }, 
        "brief_summary": {
            "textblock": "Single-arm, open-label study to evaluate the safety, tolerability and pharmacokinetics of\n      KRP203 in patients undergoing allogeneic hemopoietic stem cell transplant for hematological\n      malignancies"
        }, 
        "brief_title": "A Single Arm, Open-label Study to Evaluate the Safety and Tolerability of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hematological Malignancies", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Hematologic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Patients aged 18 to 65 years, inclusive\n\n          -  Patients must have a hematological malignancy that as per standard medical practice\n             requires myeloablative conditioning (including short term myeloablative reduced\n             intensity conditioning) followed by allogeneic hematopoetic stem cell transplant\n\n               -  Karnofsky Performance status \u226560%.\n\n               -  Suitable stem cell source available according to the graft selection algorithm\n                  using T-cell replete peripheral stem cells as a graft source\n\n        Exclusion Criteria:\n\n          -  Resting heart rate below 55\n\n          -  Significant cardiac disease (such as arrhytmia, heart failure) or any significant\n             condition which in the investigators opinion would make the patient ineligible\n\n               -  Previous allogeneic HSCT\n\n               -  Any drug required that is not compatible with KRP203 (e.g. beta-blockers or\n                  anti-thymocyte globulin)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01830010", 
            "org_study_id": "CKRP203A2105"
        }, 
        "intervention": {
            "arm_group_label": "KRP203", 
            "description": "All subjects will receive KRP203 for 111 days", 
            "intervention_name": "KRP203", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Basel", 
                    "country": "Switzerland", 
                    "zip": "4031"
                }, 
                "name": "Novartis Investigative Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-arm, Open-label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KRP203 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for Hematological Malignancies", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety and tolerability of KRP203 in patients undergoing allogeneic hematopoetic stem cell transplant for hematological malignancies", 
            "measure": "Number of participants with Adverse Events as a Measure of safety", 
            "safety_issue": "Yes", 
            "time_frame": "111 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01830010"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The main PK parameters will be determined in whole blood using non-compartmental methods. Pk parameters being measured are: AUCtau AUC during a dosing interval (tau) of 24 hours [h.ng/mL] , AUCtauR Molar ratios between KRP203-P and KRP203 based on Cmax or AUCtau", 
                "measure": "Plasma Pharmacokinetics of KRP203: Area under the Plasma Concentration-time Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "111 days"
            }, 
            {
                "description": "Cmax Maximum (peak) blood drug concentration after drug administration [ng/mL]", 
                "measure": "Plasma Pharmacokinetics (PK) of KRP203: Observed Maximum Plasma Concentration Following Drug Administration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "111 days"
            }, 
            {
                "description": "Tmax Time to reach maximum (peak) concentration [ng/mL]", 
                "measure": "Plasma Pharmacokinetics (PK) of KRP203: Time to reach the maximum concentration after drug administration", 
                "safety_issue": "No", 
                "time_frame": "111 days"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}